Viability and quantification of progenitor cells in venesected blood from patients receiving escalated-dose epirubicin and cyclophosphamide with G-CSF for lymphoma: potential role in further increasing dose-intensity. [electronic resource]
Producer: 19980129Description: 343-9 p. digitalISSN:- 1042-8194
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Blood Preservation
- Cell Count
- Cell Survival -- drug effects
- Cells, Cultured
- Cryopreservation
- Cyclophosphamide -- administration & dosage
- Dose-Response Relationship, Drug
- Epirubicin -- administration & dosage
- Erythroid Precursor Cells -- drug effects
- Granulocyte Colony-Stimulating Factor -- administration & dosage
- Hematopoietic Stem Cells -- drug effects
- Humans
- Lymphoma, Non-Hodgkin -- drug therapy
- Phlebotomy
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.